Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma, Ewing 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 1280Specimen Handling 928Carboplatin 836Magnetic Resonance Spectroscopy 831Cyclophosphamide 807Cisplatin 735Nivolumab 679Paclitaxel 634Radiotherapy 617Gemcitabine 579Biopsy 560Bevacizumab 486Dexamethasone 444fludarabine 409Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 363Fluorouracil 358atezolizumab 353durvalumab 339Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 320Blood Specimen Collection 315Standard of Care 311Pemetrexed 308Ipilimumab 303Radiation 289

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
romiplostim × 1 year × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT07048249 2026-03-18

Single Arm Romiplostim to Prevent CIT

Children's Hospital Medical Center, Cincinnati

Phase EARLY_PHASE1 Recruiting
26 enrolled
Sarcoma

Sarcoma, Ewing

NCT03362177 2026-02-11

RECITE

Amgen

Phase 3 Completed
165 enrolled 22 charts
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡